A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Safety and Efficacy of OBI-858 in Patients with Moderate-to-Severe Glabellar Lines - Poll - MDSpire

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Safety and Efficacy of OBI-858 in Patients with Moderate-to-Severe Glabellar Lines

  • By

  • Yu-Hsiu Yen

  • Tzu-Wen Tsau

  • Chih-Hung Lee

  • Hsin-Han Chen

  • Chih-Hung Lin

  • Tim-Mo Chen

  • Chi-Ming Pu

  • November 1, 2025

  • 0 min

Share

Original Source(s)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Safety and Efficacy of OBI-858 in Patients with Moderate-to-Severe Glabellar Lines

  • by Yu-Hsiu Yen, Tzu-Wen Tsau, Chih-Hung Lee, Hsin-Han Chen, Chih-Hung Lin, Tim-Mo Chen, Chi-Ming Pu

  • November 1, 2025

Related Content

Kiwifruit's Effect on Skin Examined 

Pilot study links 8 weeks of daily consumption to increased epidermal proliferation in patients with low baseline ascorbate

Injectable Targets Décolleté Wrinkles

New indication expands use of injectable biostimulator beyond the face.

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.